Valued at USD 762.26 million in 2025, the peptide synthesis market is projected to reach USD 819.62 million in 2026 and USD 1,482.67 million by 2034, growing at a CAGR of 7.7% during the forecast period 2026–2034. Key players include Bachem Holding AG, Biotage, Creative Diagnostics, GenScript, Lonza, Merck KGaA, PolyPeptide Group, Puresynth Research Chemicals Pvt Ltd., Syngene International Limited, and Thermo Fisher Scientific Inc. This analysis examines the technology, product, and application trends that pharmaceutical and biotechnology buyers should track.

Technology Landscape: SPPS, LPPS and Hybrid Approaches

Polaris segments technology into solid phase peptide synthesis (SPPS), liquid phase peptide synthesis (LPPS), and hybrid technology. Hybrid peptide synthesis is expected to grow fastest, at a 14.40% CAGR, because it combines the advantages of SPPS and LPPS, delivering higher efficiency, improved yield, and cost-effectiveness in large-scale production. It also improves the synthesis of complex and long-chain peptides, while automation and process optimization have strengthened scalability and reproducibility. Polaris adds that hybrid technology suits pharmaceutical and biotechnology applications seeking high-purity peptides for commercial and research purposes.

Innovation in liquid phase peptide synthesis is already visible: in September 2024, Cambrex launched a novel LPPS technology developed by Snapdragon Chemistry using batch reactors and continuous flow, reducing solvent use and reagent waste compared with traditional solid-phase synthesis.

Peptide-Based Therapeutics Lead Application Demand

The therapeutics segment led with an 80.14% share in 2025 as adoption of peptide-based therapeutics expands across cancer, metabolic disorders, and autoimmune conditions. Peptides offer high specificity, efficacy, and lower toxicity than traditional small molecules, and advances in formulation and delivery have improved stability and bioavailability. Demand is reinforced by disease prevalence: an August 2024 FDA report found that one in ten Americans, or 25 to 30 million people, have a rare disease.

Funding is flowing as well. Curve Therapeutics received a USD 49.2 million Series A from Pfizer Ventures in February 2024, and in April 2026 PeptiDream announced that partner Asahi Kasei Therapeutics began a Phase 1 trial of AK1940, a selective TNFR1 inhibitor. The rising focus on biologics has also strengthened demand for peptides in targeted therapies, contributing to the segment’s dominance.

Browse Full Insights:

https://www.polarismarketresearch.com/industry-analysis/peptide-synthesis-market

Reagents and Consumables Anchor Recurring Demand

By product, the reagents and consumables segment dominated with a 60.10% share in 2025, as amino acids and coupling reagents are required in every synthesis cycle. Equipment and services complete the product landscape, and high capital costs of manufacturing and purification remain a challenge. Thermo Fisher Scientific supplies chromatography and mass spectrometry instruments used to analyze and purify peptides.

Leading Suppliers: Thermo Fisher Scientific and Merck KGaA

Thermo Fisher Scientific Inc., headquartered in Waltham, Massachusetts and formed through the 2006 merger of Thermo Electron and Fisher Scientific, serves biotechnology, pharmaceutical, and healthcare sectors with laboratory supplies, equipment, instruments, and clinical and diagnostics tools. Its Invitrogen and Applied Biosystems brands offer molecular biology tools that support the discovery and development of new drugs and therapies. Merck KGaA, founded in 1668 and headquartered in Darmstadt, Germany, operates across healthcare, life science, and electronics, and its Life Science division offers solutions for protein research, cell culture, and biopharmaceutical production.

Competitive Landscape and Regional Outlook

Global leaders such as Thermo Fisher Scientific, Merck KGaA, and Bachem Holding AG leverage strong R&D capabilities and extensive distribution networks, while regional players focus on cost-effective solutions and localized services. In February 2026, Ajinomoto Bio-Pharma Services announced a strategic partnership with Olon S.p.A. to advance large-scale Peptide Synthesis  and protein manufacturing.

North America led with a 52.43% revenue share in 2025, supported by strong pharmaceutical and biotechnology research investment. Asia Pacific is projected to grow fastest at a 13.50% CAGR as pharmaceutical manufacturing capabilities expand; in June 2024, Alembic Pharmaceuticals received USFDA final approval for Icatibant Injection, a peptide product for hereditary angioedema. Supportive government initiatives and collaborations between academic institutions and biopharmaceutical companies are also fostering innovation in the region.

More Trending Latest Reports By Polaris Market Research:

Gynecological Examination Chairs Market

Fluoropolymers Market

Safari Tourism Market

Enterprise Content Management Market

Automotive Ceramics Market

Mass Flow Controller Market

Hemophilia A Treatment Market

AI Trust, Risk and Security Management Market